Abstract
The vitamin D receptor, a member of the nuclear receptor subgroup NR1I, is regulated by 1α,25(OH)2D3 to control calcium metabolism, cell proliferation and differentiation and immunomodulation. The therapeutic applications of vitamin D metabolites are wide. To develop efficient therapy, the elucidation of the structure-function relationships of VDR and its ligands are essential. In this review we will focus on the current structural understanding of the interactions of ligands in the ligand binding pocket of the VDR. These structures revealed the mutual adaptability of the ligands and the protein. In silico modeling has further revealed a possible new pocket in the VDR LBD responsible of the nongenomic action mediated by VDR. With the availability of all these structural information on VDR LBD, new ligands that are more selective, such as non-steroidal ligands, could be designed by taking into account the flexibility of some VDR regions. Tissue selectivity may also be achieved by developing ligands that specifically activate the non-genomic pathway.
Keywords: VDR, crystal structure, LBD, LBP, agonist, superagonist
Current Topics in Medicinal Chemistry
Title: Ligand Binding Domain of Vitamin D Receptors
Volume: 6 Issue: 12
Author(s): Natacha Rochel and Dino Moras
Affiliation:
Keywords: VDR, crystal structure, LBD, LBP, agonist, superagonist
Abstract: The vitamin D receptor, a member of the nuclear receptor subgroup NR1I, is regulated by 1α,25(OH)2D3 to control calcium metabolism, cell proliferation and differentiation and immunomodulation. The therapeutic applications of vitamin D metabolites are wide. To develop efficient therapy, the elucidation of the structure-function relationships of VDR and its ligands are essential. In this review we will focus on the current structural understanding of the interactions of ligands in the ligand binding pocket of the VDR. These structures revealed the mutual adaptability of the ligands and the protein. In silico modeling has further revealed a possible new pocket in the VDR LBD responsible of the nongenomic action mediated by VDR. With the availability of all these structural information on VDR LBD, new ligands that are more selective, such as non-steroidal ligands, could be designed by taking into account the flexibility of some VDR regions. Tissue selectivity may also be achieved by developing ligands that specifically activate the non-genomic pathway.
Export Options
About this article
Cite this article as:
Rochel Natacha and Moras Dino, Ligand Binding Domain of Vitamin D Receptors, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864926
DOI https://dx.doi.org/10.2174/156802606777864926 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry A Review of the Possible Mechanisms of Action of Tocotrienol – A Potential Antiosteoporotic Agent
Current Drug Targets Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology Suppression of NF-κB Activation By Gentian Violet Promotes Osteoblastogenesis and Suppresses Osteoclastogenesis
Current Molecular Medicine Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Current Advances in Retroviral Gene Therapy
Current Gene Therapy Genistein Inhibits Cell Growth and Induces Apoptosis Through Up-regulation of miR-34a in Pancreatic Cancer Cells
Current Drug Targets Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats
The Natural Products Journal β-Aryl-ς-Hydroxy-γ-Lactones: Synthesis, Structural Analysis and Cytotoxic Activity
Current Organic Synthesis Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry